PATENT CLAIM ANALYSIS

Application Number: 15750056
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "465000"]

Abstract:
The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients; and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients. The present disclosure is also directed to oral dosage forms, such as tablets or capsules comprising the disclosed blended compositions comprising the disclosed solid dispersion formulations, and the methods for making these solid dispersion formulations and pharmaceutical compositions.

Claim (Index 4):
The blended composition according to  claim 3 , wherein\n a) Compound I is present in an amount of from about 10% to about 30%, b) in the first solid dispersion formulation,\n i) Compound II is present in a concentration of from about 10% w/w to about 40% w/w, relative to the total combined weight of the first solid dispersion formulation, \n ii) the one or more pharmaceutically acceptable polymers or a mixture thereof is present in a concentration of from about 50% w/w to about 90% w/w, relative to the total combined weight of the first solid dispersion formulation, and \n iii) the one or more pharmaceutically acceptable surfactants is present in a concentration of from about 5% w/w to about 15% w/w, relative to the total combined weight of the first solid dispersion formulation; and \n c) in the second solid dispersion formulation,\n i) Compound III is present in a concentration of from about 10% w/w to about 40% w/w, relative to the total combined weight of the second solid dispersion formulation, \n ii) the one or more pharmaceutically acceptable polymers or a mixture thereof is present in a concentration of from about 10% w/w to about 70% w/w, relative to the total combined weight of the second solid dispersion formulation, and \n iii) the one or more pharmaceutically acceptable surfactants is present in a concentration of from about 3% w/w to about 10% w/w, relative to the total combined weight of the second solid dispersion formulation.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 88.0
- Lexical Diversity: 2.72881
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15128714', '15607825', '15178164', '13156783', '14006032']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7474945971921183
- 35 USC 102 Novelty (BERT): 0.5078348952188234
- Combined Prediction Score: 0.7235286269947889
- Mean Citation Score: 263.070626
- Max Citation Score: 272.1288
- Similarity Product: 193.97541077628136

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test